Micrornas in lung cancer and lung cancer bone metastases: Biomarkers for early diagnosis and targets for treatment

Recent Patents on Anti-Cancer Drug Discovery

Volumn 10, Issue 2, 2015, Pages 182-200

  Zhao, Qian ^a   Li, Ping ^a   Ma, Junrong ^a   Yu, Xijie ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Biomarker; Bone metastases; Lung cancer; MiRNA; Oncogenesis; Squamous cell carcinoma

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 101; MICRORNA 10B; MICRORNA 122; MICRORNA 124; MICRORNA 125B; MICRORNA 126; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 15A; MICRORNA 17; MICRORNA 192; MICRORNA 19B; MICRORNA 200; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 214; MICRORNA 22; MICRORNA 24; MICRORNA 29; MICRORNA 29A; MICRORNA 31; MICRORNA 34A; MICRORNA 372; MICRORNA 375; MICRORNA 9; UNCLASSIFIED DRUG; UNINDEXED DRUG; TUMOR MARKER;

ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE COURSE; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; PRIORITY JOURNAL; RNA TRANSCRIPTION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TREATMENT PLANNING; ANIMAL; BONE NEOPLASMS; EARLY CANCER DIAGNOSIS; GENETICS; LUNG NEOPLASMS; PATENT; PATHOLOGY; QUALITY OF LIFE; SECONDARY;

ANIMALS; BIOMARKERS, TUMOR; BONE NEOPLASMS; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; MICRORNAS; PATENTS AS TOPIC; QUALITY OF LIFE;

EID: 84930909075     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892810666150120163617     Document Type: Article

References (189)

1. [1] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277-300.
2. Ferlay J, Shin H, Bray F, Foman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide. Available at: http://globocan.iarc.fr/Default.aspx (Accessed on: December 15, 2014).
3. [3] Katakami N, Kunikane H, Takeda K, Takayama K, Sawa T, Saito H, et al. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol 2014; 9(2): 231-8.
4. [4] Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19(15): 3562-71.
5. [5] Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30(4): 460-71.
6. [6] Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, et al. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res 2009; 19(7): 1175-83.
7. [7] Kozomara A, Griffiths-Jones S. MiR Base: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014; 42(Database issue): D68-73.
8. [8] Du L, Pertsemlidis A. MicroRNAs and lung cancer: Tumors and 22-mers. Cancer Metastasis Rev 2010; 29(1): 109-22.
9. [9] Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y, et al. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 overexpression in advanced colorectal cancer. Hum Immunol 2014; 75(4): 348-53.
10. [10] Chan JK, Blansit K, Kiet T, Sherman A, Wong G, Earle C, et al. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol 2014; 132(3): 739-44.
11. [11] Ding Y, Wu M, Liu J, Wu C, Huang R, Zhu R, et al. Seed-targeting anti-miR-21 inhibiting malignant progression of retinoblastoma and analysis of their phosphorylation signaling pathways. Exp Eye Res 2014; 122: 1-8.
12. [12] Dong G, Liang X, Wang D, Gao H, Wang L, Wang L, et al. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol 2014; 31(7): 57.
13. [13] Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012; 29(2): 618-26.
14. [14] Wang XC, Wang W, Zhang ZB, Zhao J, Tan XG, Luo JC. Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. Radiat Oncol 2013; 8: 146.
15. [15] Wang Y, Shi J, Wu Y, Xu W, Wang Q, Zhang J, et al. Use of Luminex xMAP bead-based suspension array for detecting microRNA in NSCLC tissues and its clinical application. Tumori 2012; 98(6): 792-9.
16. [16] Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011; 30(6): 407-14.
17. [17] Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010; 411(11-12): 846-52.
18. [18] Wu R, Jiang Y, Wu Q, Li Q, Cheng D, Xu L, et al. Diagnostic value of microRNA-21 in the diagnosis of lung cancer: Evidence from a meta-analysis involving 11 studies. Tumour Biol 2014; 35(9): 8829-36.
19. [19] Wang N, Zhou Y, Zheng L, Li H. MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. Gynecol Oncol 2014; 134(1): 129-37.
20. [20] Vire E, Curtis C, Davalos V, Git A, Robson S, Villanueva A, et al. The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Mol Cell 2014; 53(5): 806-18.
21. [21] Siow MY, Ng LP, Chong VK, Jamaludin M, Abraham MT, Abdul Rahman ZA, et al. Dysregulation of miR-31 and miR-375 expression is associated with clinical outcomes in oral carcinoma. Oral Dis 2014; 20(4): 345-51.
22. [22] Manceau G, Imbeaud S, Thiebaut R, Liebaert F, Fontaine K, Rousseau F, et al. Hsa-miR-31-3p expression is linked to progressionfree survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 2014; 20(12): 3338-47.
23. [23] Karnuth B, Dedy N, Spieker T, Lawlor ER, Gattenlohner S, Ranft A, et al. Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: Low miR-31 expression with effects on proliferation and invasion. PLoS One 2014; 9(3): e93067.
24. [24] Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013; 73(3): 1232-44.
25. [25] Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res 2013; 19(19): 5423-33.
26. [26] Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, et al. Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 2014; 14: 448.
27. [27] Chen L, Jiang K, Jiang H, Wei P. MiR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. Exp Ther Med 2014; 8(2): 527-32.
28. [28] Li W, Han W, Zhao X, Wang H. Changes of expression of miR-155 in colitis-associated colonic carcinogenesis. Zhonghua Zhong Liu Za Zhi 2014; 36(4): 257-62.
29. [29] Yu ZH, Teng M, Sun AJ, Yu LL, Hu B, Qu LH, et al. Virusencoded miR-155 ortholog is an important potential regulator but not essential for the development of lymphomas induced by very virulent Marek's disease virus. Virology 2014; 448: 55-64.
30. [30] Zhu X, Wang Y, Sun Y, Zheng J, Zhu D. MiR-155 up-regulation by LMP1 DNA contributes to increased nasopharyngeal carcinoma cell proliferation and migration. Eur Arch Otorhinolaryngol 2014; 271(7): 1939-45.
31. [31] Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011; 4(6): 575-86.
32. [32] Jurkovicova D, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, Gibadulinova A, et al. MiR-155 as a diagnostic and prognostic marker in hematological and solid malignancies. Neoplasma 2014; 61(3): 241-51.
33. [33] Yao Q, Sun JG, Ma H, Zhang AM, Lin S, Zhu CH, et al. Monitoring microRNAs using a molecular beacon in CD133+/ CD338+ human lung adenocarcinoma-initiating A549 cells. Asian Pac J Cancer Prev 2014; 15(1): 161-6.
34. [34] Yu F, Jia X, Du F, Wang J, Wang Y, Ai W, et al. MiR-155-deficient bone marrow promotes tumor metastasis. Mol Cancer Res 2013; 11(8): 923-36.
35. [35] Langevin SM, Christensen BC. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: A systematic review and meta-analysis. Cancer Med 2014; 3(5): 1385-95.
36. [36] Kobayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD, Rice GE. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med 2014; 12: 4.
37. [37] Haselmann V, Kurz A, Bertsch U, Hubner S, Olempska-Muller M, Fritsch J, et al. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 2014; 146(1): 278-90.
38. [38] Xie K, Liu J, Zhu L, Liu Y, Pan Y, Wen J, et al. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol 2013; 37(6): 998-1002.
39. [39] Wang L, Yuan C, Lv K, Xie S, Fu P, Liu X, et al. Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and Let-7 signaling. PLoS One 2013; 8(6): e67373.
40. [40] Willenbrock S, Wagner S, Reimann-Berg N, Moulay M, Hewicker-Trautwein M, Nolte I, et al. Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model. PLoS One 2014; 9(6): e98788.
41. [41] Deng B, Sun Z, Jason W, Yang P. Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients. Ann Surg Oncol 2013; 20 (Suppl 3): S701-8.
42. [42] Zhang YK, Zhu WY, He JY, Chen DD, Huang YY, Le HB, et al. MiRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes. J Cancer Res Clin Oncol 2012; 138(10): 1641-50.
43. [43] Xia Y, Zhu Y, Zhou X, Chen Y. Low expression of let-7 predicts poor prognosis in patients with multiple cancers: A meta-analysis. Tumour Biol 2014; 35(6): 5143-8.
44. [44] Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, et al. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett 2014; 342(1): 43-51.
45. [45] Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene 2014; [Epub ahead of print].
46. [46] Plaisier CL, Pan M, Baliga NS. A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res 2012; 22(11): 2302-14.
47. [47] Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, et al. MiRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin beta1 and matrix metalloproteinase2 (MMP2). PLoS One 2013; 8(8): e70192.
48. [48] Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X, et al. HsamiR-125a-3p and hsa-miR-125a-5p are downregulated in nonsmall cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 2010; 10: 318.
49. [49] Xie L, Yang Z, Li G, Shen L, Xiang X, Liu X, et al. Genome-wide identification of bone metastasis-related microRNAs in lung adenocarcinoma by high-throughput sequencing. PLoS One 2013; 8(4): e61212.
50. [50] Li Y, Chao Y, Fang Y, Wang J, Wang M, Zhang H, et al. MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b. J Exp Clin Cancer Res 2013; 32: 33.
51. [51] Weng H, Huang H, Dong B, Zhao P, Zhou H, Qu L. Inhibition of miR-17 and miR-20a byoridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res 2014; 74(16): 4409-19.
52. [52] Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 2014; 110(10): 2462-71.
53. [53] Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L, et al. MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PLoS One 2014; 9(4): e94639.
54. [54] Cui SY, Huang JY, Chen YT, Song HZ, Feng B, Huang GC, et al. Let-7c governs the acquisition of chemo-or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxelresistant lung adenocarcinoma. Mol Cancer Res 2013; 11(7): 699-713.
55. [55] Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Qian J, et al. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer 2014; 110(2): 353-62.
56. Huang J, Wu J, Li Y, Li X, Yang T, Yang Q, et al. Deregulation of serum microRNA expression is associated with cigarette smoking and lung cancer. Biomed Res Int 2014; 2014: Article ID 364316.
57. [57] Mitra R, Edmonds MD, Sun J, Zhao M, Yu H, Eischen CM, et al. Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer. RNA 2014; 20(9): 1356-68.
58. [58] Zhang J, Xu L, Yang Z, Lu H, Hu D, Li W, et al. MicroRNA-10b indicates a poor prognosis of non-small cell lung cancer and targets E-cadherin. Clin Transl Oncol 2014; [Epub ahead of print].
59. [59] Zhao ZG, Jin JY, Zhang AM, Zhang LP, Wang XX, Sun JG, et al. MicroRNA profile of tumorigenic cells during carcinogenesis of lung adenocarcinoma. J Cell Biochem 2014; [Epub ahead of print].
60. [60] Chatterjee A, Chattopadhyay D, Chakrabarti G. MiR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One 2014; 9(4): e95716.
61. [61] Molina-Pinelo S, Pastor MD, Suarez R, Romero-Romero B, Gonzalez De la Pena M, Salinas A, et al. MicroRNA clusters: Dysregulation in lung adenocarcinoma and COPD. Eur Respir J 2014; 43(6): 1740-9.
62. [62] Wu C, Cao Y, He Z, He J, Hu C, Duan H, et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med 2014; 232(2): 85-95.
63. [63] Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010; 127(12): 2870-8.
64. [64] Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM, De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol 2011; 104(7): 847-51.
65. [65] Hu X, Zhang F, Liu XR, Wu YT, Ni YM. Efficacy and potential microRNA mechanism for computed tomography-guided percutaneous radiofrequency ablation of primary lung cancer and lung metastasis from liver cancer. Cell Physiol Biochem 2014; 33(5): 1261-71.
66. [66] Boldrini L, Giordano M, Ali G, Melfi F, Romano G, Lucchi M, et al. P2X7 mRNA expressionin non-small cell lung cancer: microRNA regulation and prognostic value. Oncol Lett 2015; 9(1): 449-53.
67. [67] Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 2014; 229(1): 97-9.
68. [68] Joerger M, Baty F, Fruh M, Droege C, Stahel RA, Betticher DC, et al. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85(2): 306-13.
69. [69] Zhu W, He J, Chen D, Zhang B, Xu L, Ma H, et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One 2014; 9(2): e87780.
70. [70] Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, et al. MicroRNA-30a inhibits epithelial-tomesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012; 130(9): 2044-53.
71. [71] Chen JC, Su YH, Chiu CF, Chang YW, Yu YH, Tseng CF, et al. Suppression of dicer increases sensitivity to gefitinib in human lung cancer cells. Ann Surg Oncol 2014; 21 (Suppl 4): 555-63.
72. [72] Dmitrovsky, E., Liu, X., Freemantle, S., Sempere, L.F., Cole, C., Kauppinen, S., Bak, M., Christensen, M. MicroRNA biomarkers for human breast and lung cancer. US20130296399 (2013).
73. [73] Shi Y, Liu C, Liu X, Tang DG, Wang J. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One 2014; 9(3): e90022.
74. [74] Zhao J, Kelnar K, Bader AG. In-depth analysis shows synergy between erlotinib and miR-34a. PLoS One 2014; 9(2): e89105.
75. [75] Wang LG, Ni Y, Su BH, Mu XR, Shen HC, Du JJ. MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol 2013; 42(3): 957-62.
76. [76] Ho CS, Yap SH, Phuah NH, In LL, Hasima N. MicroRNAs associated with tumour migration, invasion and angiogenic properties in A549 and SK-Lu1 human lung adenocarcinoma cells. Lung Cancer 2014; 83(2): 154-62.
77. [77] Yin J, Wang M, Jin C, Qi Q. MiR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol Lett 2014; 7(2): 461-5.
78. [78] Zhu X, Zhang X, Wang H, Song Q, Zhang G, Yang L, et al. MTA1 gene silencing inhibits invasion and alters the microRNA expression profile of human lung cancer cells. Oncol Rep 2012; 28(1): 218-24.
79. [79] Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. PLoS One 2013; 8(11): e81408.
80. [80] Lu W, Li S, Liu B, Li Y, Luo M, Sun L, et al. Screening of metastasis-related microRNAs in the large-cell lung cancer cell lines with different metastastic potentials. Zhongguo Fei Ai Za Zhi 2011; 14(11): 835-40.
81. [81] Kim MK, Jung SB, Kim JS, Roh MS, Lee JH, Lee EH, et al. Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch 2014; 465(4): 463-71.
82. [82] Tan W, Gu J, Huang M, Wu X, Hildebrandt MA. Epigenetic analysis of microRNA genes in tumors from surgically resected lung cancer patients and association with survival. Mol Carcinog 2014; [Epub ahead of print].
83. [83] Hu J, Cheng Y, Li Y, Jin Z, Pan Y, Liu G, et al. MicroRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C. Eur J Cancer 2014; 50(13): 2336-50.
84. [84] Liu MX, Zhou KC, Cao Y. MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelialmesenchymal transition and metastasis in non-small cell lung cancer. Mol Cancer 2014; 13(1): 245.
85. [85] Wang XC, Tian LL, Wu HL, Jiang XY, Du LQ, Zhang H, et al. Expression of miRNA-130a in nonsmall cell lung cancer. Am J Med Sci 2010; 340(5): 385-8.
86. [86] Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, et al. MiR-134/487b/655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 2014; 13(2): 444-53.
87. [87] Yang H, Tang Y, Guo W, Du Y, Wang Y, Li P, et al. Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells. Tumour Biol 2014; 35(7): 6557-65.
88. [88] Gao Y, Fan X, Li W, Ping W, Deng Y, Fu X. MiR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun 2014; 446(1): 179-86.
89. [89] Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, Wang Y, et al. MicroRNA-143 inhibits migration and invasion of human non-smallcell lung cancer and its relative mechanism. Int J Biol Sci 2013; 9(7): 680-92.
90. [90] Zeng XL, Zhang SY, Zheng JF, Yuan H, Wang Y. Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer. Chin Med J (Engl) 2013; 126(23): 4510-6.
91. [91] Chiou GY, Cherng JY, Hsu HS, Wang ML, Tsai CM, Lu KH, et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release 2012; 159(2): 240-50.
92. [92] Zhao C, Xu Y, Zhang Y, Tan W, Xue J, Yang Z, et al. Downregulation of miR-145 contributes to lung adenocarcinoma cell growth to form brain metastases. Oncol Rep 2013; 30(5): 2027-34.
93. [93] Wang F, Chan LW, Law HK, Cho WC, Tang P, Yu J, et al. Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA: miRNA regression model supported by target prediction databases. Genomics 2014; 104(6 Pt B): 504-11.
94. [94] Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 2012; 33(5): 1046-54.
95. [95] Li J, Yang H, Li Y, Liu Y, Chen S, Qi C, et al. MicroRNA-146 upregulation predicts the prognosis of non-small cell lung cancer by miRNA in situ hybridization. Exp Mol Pathol 2014; 96(2): 195-9.
96. [96] Cornett AL, Lutz CS. Regulation of COX-2 expression by miR-146a in lung cancer cells. RNA 2014; 20(9): 1419-30.
97. [97] Chen Y, Min L, Zhang X, Hu S, Wang B, Liu W, et al. Decreased miRNA-148a is associated with lymph node metastasis and poor clinical outcomes and functions as a suppressor of tumor metastasis in non-small cell lung cancer. Oncol Rep 2013; 30(4): 1832-40.
98. [98] Xu W, Ji J, Xu Y, Liu Y, Shi L, Liu Y, et al. MicroRNA-191, by promoting the EMT and increasing CSC-like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells. Mol Carcinog 2014; [Epub ahead of print].
99. [99] Skrzypski M, Czapiewski P, Goryca K, Jassem E, Wyrwicz L, Pawlowski R, et al. Prognostic value of microRNA expression in operable non-small cell lung cancer patients. Br J Cancer 2014; 110(4): 991-1000.
100. [100] Valencia K, Luis-Ravelo D, Bovy N, Anton I, Martinez-Canarias S, Zandueta C, et al. MiRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol Oncol 2014; 8(3): 689-703.
101. [101] Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, et al. MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene 2014; [Epub ahead of print].
102. [102] Liang H, Liu M, Yan X, Zhou Y, Wang W, Wang X, et al. MiR-193a-3p functions as a tumor suppressor in lung cancer by downregulating ERBB4. J Biol Chem 2014; 290(2): 926-40.
103. [103] Wu X, Liu T, Fang O, Leach LJ, Hu X, Luo Z. MiR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27(kip1). Oncogene 2014; 33(12): 1506-14.
104. [104] Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, et al. MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB. Cancer Lett 2014; 347(1): 65-74.
105. [105] Kang Z, Li Y, He X, Jiu T, Wei J, Tian F, et al. Quantitative assessment of the association between miR-196a2 rs11614913 polymorphism and cancer risk: Evidence based on 45,816 subjects. Tumour Biol 2014; 35(7): 6271-82.
106. [106] Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M, et al. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ 2014; 21(5): 774-82.
107. [107] Pacurari M, Addison JB, Bondalapati N, Wan YW, Luo D, Qian Y, et al. The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol 2013; 43(2): 548-60.
108. [108] Fang S, Zeng X, Zhu W, Tang R, Chao Y, Guo L. Zinc finger Ebox-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer. Exp Mol Pathol 2014; 96(3): 438-44.
109. [109] Liu W, Huang YJ, Liu C, Yang YY, Liu H, Cui JG, et al. Inhibition of TBK1 attenuates radiation-induced epithelial-mesenchymal transition of A549 human lung cancer cells via activation of GSK-3beta and repression of ZEB1. Lab Invest 2014; 94(4): 362-70.
110. [110] Salim H, Arvanitis A, de Petris L, Kanter L, Haag P, Zovko A, et al. MiRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer 2013; 52(10): 895-911.
111. [111] Wang RT, Xu M, Song ZG, Xu CX, Jin H. Decreased expression of miR-216a contributes to non-small cell lung cancer progression. Clin Cancer Res 2014; 20(17): 4705-16.
112. [112] Zhang C, Ge S, Hu C, Yang N, Zhang J. MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in nonsmall cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 2013; 45(12): 1055-61.
113. [113] Wang H, Zhu LJ, Yang YC, Wang ZX, Wang R. MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G(1)/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer 2014; 111(2): 339-54.
114. [114] Vaira V, Faversani A, Martin NM, Garlick DS, Ferrero S, Nosotti M, et al. Regulation of lung cancer metastasis by Klf4-Numb-like signaling. Cancer Res 2013; 73(8): 2695-705.
115. [115] Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 2011; 129(11): 2621-31.
116. [116] Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Yang Y, et al. MiR-335 inhibits small cell lung cancer bone metastases via IGFIR and RANKL pathways. Mol Cancer Res 2014; 12(1): 101-10.
117. Li Y, Zhao W, Bao P, Li C, Ma XQ, Li Y, et al. MiR-339-5p inhibits cell migration and invasion and may be associated with the tumor-node-metastasis staging and lymph node metastasis of nonsmall cell lung cancer. Oncol Lett 2014; 8(2): 719-25.
118. [118] Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, et al. A microRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res 2014; 20(12): 3107-17.
119. [119] Lai JH, She TF, Juang YM, Tsay YG, Huang AH, Yu SL, et al. Comparative proteomic profiling of human lung adenocarcinoma cells (CL 1-0) expressing miR-372. Electrophoresis 2012; 33(4): 675-88.
120. [120] Wang Y, Xia H, Zhuang Z, Miao L, Chen X, Cai H. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis 2014; 5: e1227.
121. [121] Yu H, Jiang L, Sun C, Li Guo L, Lin M, Huang J, et al. Decreased circulating miR-375: A potential biomarker for patients with nonsmall-cell lung cancer. Gene 2014; 534(1): 60-5.
122. Shao Y, Geng Y, Gu W, Huang J, Ning Z, Pei H. Prognostic significance of microRNA-375 downregulation in solid tumors: A meta-analysis. Dis Markers 2014; 2014: Article ID 626185.
123. [123] Yan JW, Lin JS, He XX. The emerging role of miR-375 in cancer. Int J Cancer 2014; 135(5): 1011-8.
124. [124] Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S, et al. MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes. Biochem Biophys Res Commun 2014; 450(1): 154-9.
125. [125] Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011; 30(23): 2644-58.
126. [126] Wang XC, Tian LL, Jiang XY, Wang YY, Li DG, She Y, et al. The expression and function of miRNA-451 in non-small cell lung cancer. Cancer Lett 2011; 311(2): 203-9.
127. [127] Chen D, Huang J, Zhang K, Pan B, Chen J, De W, et al. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting protooncogene c-Myc. Eur J Cancer 2014; 50(17): 3050-67.
128. [128] Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J, et al. MiR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res 2014; 74(11): 303-42.
129. [129] Zhang HH, Pang M, Dong W, Xin JX, Li YJ, Zhang ZC, et al. MiR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep 2014; 31(3): 1473-9.
130. [130] Yu YH, Chen HA, Chen PS, Cheng YJ, Hsu WH, Chang YW, et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene 2013; 32(4): 431-43.
131. [131] Mo X, Zhang F, Liang H, Liu M, Li H, Xia H. MiR-544a promotes the invasion of lung cancer cells by targeting cadherina 1 in vitro. Onco Targets Ther 2014; 7: 895-900.
132. [132] Du B, Wang Z, Zhang X, Feng S, Wang G, He J, et al. MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells. PLoS One 2014; 9(2): e88022.
133. [133] Liu C, Yang H, Xu Z, Li D, Zhou M, Xiao K, et al. MicroRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway. J Cancer Res Clin Oncol 2014; [Epub ahead of print].
134. [134] Cao JX, Lu Y, Qi JJ, An GS, Mao ZB, Jia HT, et al. MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells. Cell Death Dis 2014; 5: e1426.
135. [135] Subramani A, Alsidawi S, Jagannathan S, Sumita K, Sasaki AT, Aronow B, et al. The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis. Sci Rep 2013; 3: 2392.
136. [136] Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res 2013; 73(11): 3326-35.
137. [137] Ma J, Mannoor K, Gao L, Tan A, Guarnera MA, Zhan M, et al. Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. Mol Oncol 2014; 8(7): 1208-19.
138. [138] Yoo JK, Jung HY, Lee JM, Yi H, Oh SH, Ko HY, et al. The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1. Cell Death Differ 2014; 21(7): 1150-9.
139. [139] Vimalraj S, Miranda PJ, Ramyakrishna B, Selvamurugan N. Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers 2013; 35(5): 369-87.
140. [140] Hu H, Zhang Y, Cai XH, Huang JF, Cai L. Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett 2012; 4(5): 1037-42.
141. [141] Zhang J, Tu Q, Bonewald LF, He X, Stein G, Lian J, et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J Bone Miner Res 2011; 26(8): 1953-63.
142. [142] Horie T, Baba O, Kuwabara Y, Yokode M, Kita T, Kimura T, et al. MicroRNAs and lipoprotein metabolism. J Atheroscler Thromb 2014; 21(1): 17-22.
143. [143] Cao R, Bai Y, Sun L, Zheng J, Zu M, Du G, et al. Xuezhikang therapy increases miR-33 expression in patients with low HDL-C levels. Dis Markers 2014; 2014: 781780.
144. [144] Allen RM, Marquart TJ, Jesse JJ, Baldan A. Control of very lowdensity lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33. Circ Res 2014; 115(1): 10-22.
145. [145] Bae CR, Hasegawa K, Akieda-Asai S, Kawasaki Y, Senba K, Cha YS, et al. Possible involvement of food texture in insulin resistance and energy metabolism in male rats. J Endocrinol 2014; 222(1): 61-72.
146. [146] Canfran-Duque A, Ramirez CM, Goedeke L, Lin CS, Fernandez-Hernando C. MicroRNAs and HDL life cycle. Cardiovasc Res 2014; 103(3): 414-22.
147. [147] Sun X, Feinberg MW. MicroRNA-management of lipoprotein homeostasis. Circ Res 2014; 115(1): 2-6.
148. [148] Goedeke L, Salerno A, Ramirez CM, Guo L, Allen RM, Yin X, et al. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med 2014; 6(9): 1133-41.
149. [149] Dougherty KM, Blomme EA, Koh AJ, Henderson JE, Pienta KJ, Rosol TJ, et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999; 59(23): 6015-22.
150. [150] Kuo PL, Liao SH, Hung JY, Huang MS, Hsu YL. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta 2013; 1830(6): 3756-66.
151. [151] Gong JN, Yu J, Lin HS, Zhang XH, Yin XL, Xiao Z, et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ 2014; 21(1): 100-12.
152. [152] Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z. Prognostic value of miR-29a expression in pediatric acute myeloid leukemia. Clin Biochem 2013; 46(1-2): 49-53.
153. [153] Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 2012; 7(10): e48086.
154. [154] Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology 2014; 60(5): 1645-58.
155. [155] Wang HB, Zhang HJ, Su JM, Zhou WY, Wang HY, Chen XF. Epithelial-mesenchymal transition (EMT) and its effect on microRNA expression in lung cancer. Zhonghua Zhong Liu Za Zhi 2011; 33(8): 590-3.
156. [156] He, X., Liang, L., Lu, S., Chen, Z., Yu, Y. MicroRNA markers for discriminating constitutional lung cancer tissue and paracancerous tissue. CN102851282 (2013) & CN102851283 (2013).
157. [157] Annilo, T., Tonisson, N., Vooder, T., Kirotar, K., Vosa, U., Vaelk, K., Kolde, R., Roosipuu, R., Vilo, J., Metspalu, A. Methylation and microRNA markers of early-stage non-small cell lung cancer. WO2012175562 (2012).
158. [158] Jassem, J., Skrzypski, M. Markers and methods for determining risk of distant recurrence of non-small cell lung cancer in stage IIIIA patients. US2012309638 (2012).
159. [159] Skrzypski, M., Jassem, J. Determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage I-IIIA. US2012130648 (2012).
160. [160] Taylor, D., Gercel-Taylor, C. MicroRNA biomarkers. WO2013022786 (2014).
161. [161] Beaudenon, S., Elizondo, L., Doleshal, M., Brown, D., Labourier, E. MiRNAs differentially expressed in lymph nodes from cancer patients. US2014141423 (2014).
162. [162] Mambo, E., Brown, D., Adai, A., Sanford, T., Volz, S., Choudhary, A. MiRNA biomarkers of lung disease. US2014274791 (2014).
163. [163] Yi, Y., Zhang, W., Cao, P., Zou, Y., Li, N., Liu, C., Yuanbing, Q., Wu, X., Feng, Z. Serum/plasmanon miRNA marker for diagnosing non-small cell lung cancer at early stage and application thereof. CN103725779 (2014).
164. [164] Pan, S., Wang, F., Xu, J., Yang, R., Huang, P., Xu, T., Zhang, L., Chen, D., Zhang, Y., Xie, P., Gu, B., Jiang, Y. Non-small cell lung cancer prognosis detection composition and applications thereof. CN103602678 (2014).
165. [165] Mao, H., Wang, P.Z., Hong, L., Yang, D., Hong, Q., Jin, Q., Bai, C., Zhao, J. MicroRNA biological markers for early lung cancer diagnosis and application thereof. CN103484550 (2014).
166. [166] Showe, L.C., Showe, M., Kossenkov, A.V., Nikonova, E. Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers. US2011251098 (2011).
167. [167] Ma, Z., Jin, Y., Zhao, B., Shen, Y., Wang, Q. Application of miR-146a-5p in non-small cell lung cancer cell lines. CN103948941 (2014).
168. [168] Jin, Y., Wei, J., Ma, Z., Li, Y., Zhao, B. Application of miR-143 gene in non-small-cell lung carcinoma. CN103751801 (2014).
169. [169] Ma, Z., Jin, Y., Zhao, B., Qiu, X., Tian, K. Application of MiR-181a-5p in non-small cell lung cancer. CN103146702 (2013).
170. [170] Lou, J., Xue, J., Wang, L., Wu, C. Early-stage lung adenocarcinoma miRNA (micro ribonucleic acid) specific expression profile and reverse transcription primer and application thereof. CN103173448 (2013).
171. [171] O'driscoll, L., O'byrne, K. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. US2013059753 (2013).
172. [172] Raponi, M., Dossey, L.E. Process for predicting the prognosis of squamous cell lung cancer. US2011171657 (2011).
173. [173] Kim, S.H., Kim, Y.J., Lee, H.K., Yoon, D.H., Seo, K.S. Composition for inhibiting expression of DLK-1 gene. KR20130051520 (2013).
174. [174] Zhu, X., Yan, X., Zhao, H., Zhu, L., Ji, H. Small cell lung cancer markers and their detection. CN102899390 (2013).
175. [175] He, Z., Gu, Y., Cheng, Y., Zhang, Z., Wang, C. Application of miR-493 gene in preparation of medicament for inhibiting cancer cell proliferation. CN103656678 (2014).
176. [176] Wilcox, S., Ayers, D., Janjic, N., Gold, L., Riel-mehan, M., Jarvis, T. Lung cancer biomarkers and uses thereof. US20130116150 (2013).
177. [177] Keller, A., Beier, M. Complex miRNA sets as novel biomarkers for lung diseases. US20130331290 (2013).
178. [178] Croce, C., Yanaihara, N., Harris, C. MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer. US2011177968 (2014).
179. [179] Harris, C.C., Schetter, A.J., Okayama, H., Akagi, I. Expression of protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer. WO2014031609 (2014).
180. [180] Lu, S., Bai, C., Huang, W., Hou, Y., Wu, Y., Zhu, H. MicroRNA marker for identifying subtypes of lung cancer and application of microRNA marker. CN102839179 (2012)
181. [181] Wang, M.X., Zheng, D. Method for early detection of lung cancer. US20140038194 (2014).
182. [182] Yang, Z., Xie, L., Xu, L., Li, G. Kit for detecting changes of lung cancer cell RNA. CN102899405 (2013).
183. [183] Yang, Z., Xie, L., Xu, L., Li, G. Fluorescent quantitative polymerase chain reaction (PCR) assay kit for bone metastasis of lung cancer. CN102876788 (2013).
184. [184] Yang, Z., Xie, L., Xu, L., Li, G. Kit for detecting bone metastasis of lung cancer. CN102876789 (2013).
185. [185] Carlo, C., George, C. Compositions for use in treating BCL2-associated cancers. US2014335161 (2014).
186. [186] Chung, L., Josson, S., Gururajan, M., Jain, A. Targeting microRNAs miR--409-5P, miR-379 and miR-154* to treat prostate cancer bone metastasis and drug resistant lung cancer. US2014323551 (2014).
187. [187] Wang, P., Li, Y., Xie, S., Zhang, H., Pang, M., Zhang, C. Micro RNA expression vector and application. CN103695464 (2014).
188. [188] Sozzi, G., Pastorino, U., Boeri, M. Micro-RNA biomarkers for identifying risk of and/or for diagnosing lung tumour and pharmaceutical compositions thereof. US2012225925 (2014).
189. [189] Liu X, Fang H, Chen H, Jiang X, Fang D, Wang Y, et al. An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One 2012; 7(6): e38659.